Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:CYTK NASDAQ:ONC NASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$89.03-3.2%$95.14$79.52▼$124.00$22.51B1.361.07 million shs345,744 shsCYTKCytokinetics$75.73-3.7%$65.66$29.75▼$80.20$9.42B0.382.23 million shs826,797 shsONCBeOne Medicines$293.59-3.6%$300.53$227.05▼$385.22$32.21B0.5253,173 shs114,447 shsRVMDRevolution Medicines$141.75-5.2%$117.84$34.00▼$155.70$30.15B1.413.39 million shs563,067 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-0.26%-1.11%-6.52%-13.11%-0.10%CYTKCytokinetics+1.84%+5.86%+18.52%+18.68%+162.13%ONCBeOne Medicines-3.77%-3.91%-1.74%-11.98%+38.50%RVMDRevolution Medicines-0.31%+4.88%+1.67%+55.20%+278.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$89.03-3.2%$95.14$79.52▼$124.00$22.51B1.361.07 million shs345,744 shsCYTKCytokinetics$75.73-3.7%$65.66$29.75▼$80.20$9.42B0.382.23 million shs826,797 shsONCBeOne Medicines$293.59-3.6%$300.53$227.05▼$385.22$32.21B0.5253,173 shs114,447 shsRVMDRevolution Medicines$141.75-5.2%$117.84$34.00▼$155.70$30.15B1.413.39 million shs563,067 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech-0.26%-1.11%-6.52%-13.11%-0.10%CYTKCytokinetics+1.84%+5.86%+18.52%+18.68%+162.13%ONCBeOne Medicines-3.77%-3.91%-1.74%-11.98%+38.50%RVMDRevolution Medicines-0.31%+4.88%+1.67%+55.20%+278.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.72Moderate Buy$130.6047.03% UpsideCYTKCytokinetics 2.82Moderate Buy$98.5529.09% UpsideONCBeOne Medicines 2.79Moderate Buy$391.0032.00% UpsideRVMDRevolution Medicines 3.10Buy$103.88-27.84% DownsideCurrent Analyst Ratings BreakdownLatest CYTK, ONC, RVMD, and BNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026BNTXBioNTech Berenberg BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$155.00 ➝ $140.005/12/2026CYTKCytokinetics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$92.00 ➝ $97.005/11/2026CYTKCytokinetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$136.00 ➝ $140.005/7/2026ONCBeOne Medicines Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$395.005/7/2026ONCBeOne Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$410.00 ➝ $420.005/7/2026RVMDRevolution Medicines GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$205.005/7/2026ONCBeOne Medicines BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $409.005/7/2026CYTKCytokinetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$95.00 ➝ $105.005/7/2026ONCBeOne Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$423.00 ➝ $425.005/7/2026ONCBeOne Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$411.00 ➝ $413.005/7/2026RVMDRevolution Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$165.00(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$3.25B6.92$1.29 per share69.08$86.54 per share1.03CYTKCytokinetics$88.04M107.90N/AN/A($6.64) per share-11.50ONCBeOne Medicines$5.74B5.66$3.66 per share80.99$43.39 per share6.83RVMDRevolution Medicines$11.58M2,642.72N/AN/A$7.06 per share20.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)CYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%N/AONCBeOne Medicines$286.93M$4.4766.2728.84N/A8.94%12.06%6.69%N/ARVMDRevolution Medicines-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%N/ALatest CYTK, ONC, RVMD, and BNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RVMDRevolution Medicines-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026BNTXBioNTech-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million4/1/2026Q1 2026ONCBeOne MedicinesN/A$0.25N/A$1.95N/A$1.51 billion2/26/2026Q4 2025ONCBeOne Medicines$1.60$0.58-$1.02$0.58$1.45 billion$1.50 billion2/25/2026Q4 2025RVMDRevolution Medicines-$1.56-$1.86-$0.30-$1.86$3.89 millionN/A2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.808.74CYTKCytokineticsN/A4.214.21ONCBeOne Medicines0.203.643.27RVMDRevolution Medicines0.196.806.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%CYTKCytokineticsN/AONCBeOne Medicines48.55%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%CYTKCytokinetics2.60%ONCBeOne Medicines6.19%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech7,807252.88 million204.33 millionOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableONCBeOne Medicines12,000109.72 million102.93 millionN/ARVMDRevolution Medicines250212.60 million195.16 millionOptionableCYTK, ONC, RVMD, and BNTX HeadlinesRecent News About These CompaniesCancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report1 hour ago | benzinga.comAIHC Capital Management Ltd Acquires New Holdings in Revolution Medicines, Inc. $RVMDMay 15 at 3:08 AM | marketbeat.comRevolution Medicines Advances Daraxonrasib Into Phase 3 Pancreatic Cancer Trial, Raising Long-Term Upside PotentialMay 14 at 1:10 PM | tipranks.comUS cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drugMay 14 at 6:04 AM | reuters.comQ2 EPS Forecast for Revolution Medicines Lowered by AnalystMay 11, 2026 | marketbeat.comRevolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for DaraxonrasibMay 10, 2026 | insidermonkey.comIs It Too Late To Consider Revolution Medicines (RVMD) After A 240% One Year Surge?May 10, 2026 | finance.yahoo.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $165.00May 10, 2026 | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) Price Target Raised to $172.00 at Piper SandlerMay 8, 2026 | americanbankingnews.comRevolution Medicines Warrants: Balancing Dilution Risk and Potential Worthlessness Ahead of 2026 ExpiryMay 8, 2026 | tipranks.comRevolution Medicines Signals Breakout With RAS WinsMay 7, 2026 | tipranks.comRoyal Bank Of Canada Increases Revolution Medicines (NASDAQ:RVMD) Price Target to $165.00May 7, 2026 | marketbeat.comRVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewMay 7, 2026 | zacks.comRevolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comRevolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Wedbush Analyst SaysMay 7, 2026 | marketbeat.comPiper Sandler Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock PriceMay 7, 2026 | marketbeat.comComerica Bank Sells 466,931 Shares of Revolution Medicines, Inc. $RVMDMay 7, 2026 | marketbeat.comRevolution Medicines Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPSMay 6, 2026 | marketbeat.comRevolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic CancerMay 6, 2026 | globenewswire.comPromising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effectsMay 6, 2026 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbott Stock Crash: Rebound Could Be Coming FastBy Thomas Hughes | April 17, 2026Allbirds Exits Shoes, Pivots to AI With NewBird RebrandBy Leo Miller | April 21, 2026Spotify’s Ad Slump Raises a Bigger Question Than You ThinkBy Chris Markoch | April 29, 20263 Emerging Markets ETFs to Maximize Exposure to High-Potential CountriesBy Nathan Reiff | May 4, 2026Palantir Drops After a Blowout Q1—What Investors Should KnowBy Chris Markoch | May 5, 2026CYTK, ONC, RVMD, and BNTX Company DescriptionsBioNTech NASDAQ:BNTX$89.03 -2.96 (-3.22%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Cytokinetics NASDAQ:CYTK$75.73 -2.91 (-3.70%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.BeOne Medicines NASDAQ:ONC$293.58 -11.04 (-3.62%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Revolution Medicines NASDAQ:RVMD$141.75 -7.72 (-5.16%) As of 01:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy? Dividend Growth or High Yield: The Income Investor's Bet Karman: Defense Darling's Outlook Strengthens After 40% Drop Nebius Upside Expands as AI Feedback Loop Intensifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
